ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Aptamer Engineering: Strategies for Discovering Functional Nucleic Acids for Next-Generation Diagnostics and Biosensing.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From Molecular Recognition to Clinical Readout: Design Principles for Functional Nucleic Acid-Material Biosensors in Medical Diagnostics.Molecules (Basel, Switzerland) · 2026Review
- A Fentanyl-Responsive Microneedle Patch for Harm Reduction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Target-Displaced Aptamer-cDNA Duplex Strategy on ERGO for Ultrasensitive Turn-On Electrochemical Detection of Ochratoxin A.Sensors (Basel, Switzerland) · 2026Article
- Aptamer Engineering: Strategies for Discovering Functional Nucleic Acids for Next-Generation Diagnostics and Biosensing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Aptamers are highly selective nucleic acid ligands that overcome many challenges of antibodies, including structural instability and high production costs. The implementation of aptamers into routine research and commercial applications has advanced steadily, though it has been tempered by the limitations of existing discovery methods, which remain relatively slow and low-throughput. SELEX, the gold-standard method for aptamer discovery, has played a pivotal role in the field. As the demand for faster and more tailored solutions grows, there is increasing recognition of the value of newer approaches that can expedite the discovery and optimization of aptamers for specific applications. This review discusses recent advances in the methods used for aptamer engineering, including both wet lab methods performed in vitro, and dry lab methods performed in silico. Applications of engineered aptamers described in recent literature and discuss new developments that could further lead to innovative new applications of aptamers for use both within and outside of the laboratory are discussed. Within the laboratory, these applications include (but are not limited to) target-binding assays and integration into analytical nanomaterials, and outside of the laboratory, diagnostics and biosensing, which will be discussed at length.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.